TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00755716
Drug: Placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive
Study: NCT02101554
Drug: Ages 7-11
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Study: NCT02101554
Drug: ages 12-17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Study: NCT00640146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Study: NCT01883297
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
Study: NCT04127695
Drug: Placebo ABBV-0805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ABBV-0805 administered by IV infusion.
Study: NCT01708720
Drug: IPV
Normalized name: IPV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393689
Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
Study: NCT04055467
Drug: [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain imaging of alpha-7 nicotinic acetylcholine receptors
Study: NCT01708720
Drug: Adjuvanted Sabin-IPV
Normalized name: Juniperus sabina leaf
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00958971
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
Study: NCT01975701
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral use.
Study: NCT04005807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT01717391
Drug: fluorothymidine F 18
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
Study: NCT01301183
Drug: RhIGF-1 with transdermal 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
Study: NCT01301183
Drug: Placebo and transdermal 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
Study: NCT04161976
Drug: LY900027
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY900027 administered to participants with T1DM using CSII.
Study: NCT01928888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
Study: NCT03761849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection
Study: NCT00198666
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elemental Zinc
Study: NCT01272388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
Study: NCT00874172
Drug: Rapid optimized analgesic strategy
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus
Study: NCT00874172
Drug: current analgesic strategy
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration
Study: NCT04307862
Drug: ZEP-3Na 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
Study: NCT04307862
Drug: ZEP-3Na 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
Study: NCT02636972
Drug: OCPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra
Study: NCT02665624
Drug: Senna alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of bowel cleansing and patient comfort.
Study: NCT01807234
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Study: NCT01807234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one spray in each nostril and placebo one nasal spray.
Study: NCT02967770
Drug: Standard of Care Second Line Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03886688
Drug: HEC53856
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03886688
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04088305
Drug: Individualized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
Study: NCT00591084
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion placebo (group B)once a day and continued for 14 days
Study: NCT03460470
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Sildenafil
Study: NCT02771600
Drug: Topical anaesthetic cream
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT04307862
Drug: Placebo Vehicle only
Approvals — FDA: no, EMA: no, PMDA: no
Description: he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
Study: NCT02050334
Drug: CC100
Normalized name: CENTRAL LINE DRESSING KIT M#BSIPICC1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC100 reconstituted in diluent
Study: NCT02050334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent. Amount to match CC100 dose.
Study: NCT03075267
Drug: PT010 (BGF MDI) 320/14.4/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study: NCT03075267
Drug: PT010 (BGF MDI) 160/14.4/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study: NCT03075267
Drug: PT003 (GFF MDI) 14.4/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study: NCT02662023
Drug: Basal
Normalized name: Basaljel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
Study: NCT04282200
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous ketorolac 30 mg every 6 hours
Study: NCT02497547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00556296
Drug: NRP104
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRP104 30mg capsule once daily in a.m.
Study: NCT00556296
Drug: NRP104
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRP104 50mg capsule once daily in a.m.
Study: NCT00556296
Drug: NRp104
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRP104 70mg capsule once daily in a.m.
Study: NCT00556296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04332991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
Study: NCT01263223
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01263223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00000499
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01129011
Drug: PN400 (VIMOVO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
Study: NCT01129011
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg dosed twice daily (bid) orally
Study: NCT00968097
Drug: 123-I MNI-340
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
Study: NCT00291928
Drug: Part B
Normalized name: Hem-Care Premium 7-Part Blend Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
Study: NCT03423537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100IU per day containing N/S 0.9% will be injected
Study: NCT02073656
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01525875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg (one 500 mg capsule two times daily) of placebo.
Study: NCT05256758
Drug: Placental Lactogen
Normalized name: Human placental lactogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 patients randomised to receive placebo for 6 months.
Study: NCT02831088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
Study: NCT00237718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
Study: NCT00237718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for alpha lipoic acid; 2 pills daily for 6 months
Study: NCT01870687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV administration every 4 weeks from Week 0 to Week 48
Study: NCT02270606
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02270606
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00942799
Drug: Genz-644282 (28-day dosing schedule)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
Study: NCT00942799
Drug: Genz-644282 (21-day dosing schedule)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
Study: NCT01133678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
Study: NCT02720783
Drug: Placebo vaginal pessary
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04586335
Drug: CYH33
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
Study: NCT00394771
Drug: Seasonale®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
Study: NCT00394771
Drug: Portia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
Study: NCT00811993
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
Study: NCT00811993
Drug: RO1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27mg/kg iv, monotherapy
Study: NCT00811993
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT00811993
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT00811993
Drug: pemetrexel
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT05224388
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
Study: NCT02305797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01803828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg/die (1 capsule)
Study: NCT02720978
Drug: vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery.
Study: NCT01614899
Drug: SM-13496 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily orally
Study: NCT01614899
Drug: SM-13496 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily orally
Study: NCT01614899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily orally
Study: NCT04203368
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
Study: NCT03343509
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet
Study: NCT01156051
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
Study: NCT03343509
Drug: Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ointment
Study: NCT00449033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
Study: NCT01176409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
Study: NCT00684632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00684632
Drug: KW-2246 (fentanyl citrate)
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KW-2246 (fentanyl citrate)
Study: NCT00050167
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
Study: NCT03623776
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
Study: NCT04366648
Drug: JK-1201I
Approvals — FDA: no, EMA: no, PMDA: no
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology
Study: NCT02766764
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
Study: NCT02766764
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
Study: NCT04058158
Drug: SB12 (proposed eculizumab biosimilar)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Study: NCT02855892
Drug: GV1001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04143802
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04143802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00358722
Drug: Fermagate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet 500mg
Study: NCT03508882
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
Study: NCT01798238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
Study: NCT02577848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were taken daily for 7 days
Study: NCT03278808
Drug: Chloroquine-Azithromycin (CQ/AZ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
Study: NCT01931683
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
Study: NCT01052831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-100 mg qd for 8 weeks
Study: NCT02172040
Drug: Matched placebo capsule for over-encapsulated celecoxib capsule
Normalized name: celecoxib Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Study: NCT02172040
Drug: Over-encapsulated 200 mg celecoxib capsule
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Study: NCT03204045
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mL mixture of fentanyl with isotonic saline
Study: NCT01916447
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.